BioMarin Pharmaceutical | BMRN - Selling And Administration Expenses

Stock Price
57.54
Daily Change
-0.41 -0.71%
Monthly
-2.26%
Yearly
-8.48%
Q1 Forecast
54.80

BioMarin Pharmaceutical reported $223.42M in Selling and Administration Expenses for its fiscal quarter ending in September of 2025.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 124.9M 1.24M Sep/2025
Agios Pharmaceuticals USD 41.27M 4.6M Sep/2025
Alnylam Pharmaceuticals USD 262.59M 60.72M Sep/2025
Amgen USD 1.7B 9M Sep/2025
Bayer EUR 3.4B 140M Sep/2025
Biogen USD 545.2M 38.6M Sep/2025
BioMarin Pharmaceutical USD 223.42M 8.86M Sep/2025
Gilead Sciences USD 1.35B 6M Sep/2025
Incyte USD 329.08M 1.94M Sep/2025
Insmed USD 186.38M 109.94M Sep/2025
Ionis Pharmaceuticals USD 86.56M 4.04M Sep/2025
Moderna USD 268M 38M Sep/2025
Neurocrine Biosciences USD 291.6M 5.3M Sep/2025
PTC Therapeutics USD 84.05M 1.22M Sep/2025
Regeneron Pharmaceuticals USD 775M 117.2M Dec/2025
Roche Holding CHF 7.28B 3.99B Dec/2025
Sanofi EUR 2.75B 455M Dec/2025
Sarepta Therapeutics USD 77.11M 7.22M Sep/2025
Ultragenyx Pharmaceutical USD 86.62M 26K Sep/2025
United Therapeutics USD 152M 60.5M Sep/2025
Vertex Pharmaceuticals USD 445.1M 20.5M Sep/2025